Pegvisomant monotherapy once daily returns concentrations of insulin-like growth factor I (IGF-I) to normal in most patients with acromegaly, but is very costly. In a 42-week dose-finding study, we assessed the efficacy of the combination of long-acting somatostatin analogues once monthly and pegvisomant once weekly in 26 patients with active acromegaly. Dose of pegvisomant was increased until IGF-I concentration became normal or until a weekly dose of 80 mg was reached. IGF-I reached normal concentrations in 18 of 19 (95%) patients who completed 42 weeks of treatment, with a median weekly dose of 60 mg pegvisomant (range 40-80). No signs of pituitary tumour growth were noted, but mild increases in liver enzymes were observed in ten patients (38%). This combined treatment is effective, might increase compliance, and could greatly reduce the costs of medical treatment for acromegaly in some patients.

Additional Metadata
Persistent URL,
Journal The Lancet
Feenstra, J, de Herder, W.W, ten Have, S.M.T.H, van den Beld, A.W, Feelders, R.A, Janssen, J.A.M.J.L, & van der Lely, A-J. (2005). Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. The Lancet, 365(9471), 1644–1646. doi:10.1016/S0140-6736(05)63011-5